银屑病生物免疫治疗与炎症性关节炎发病时间的关联:局限性与机遇
该文基于美国电子健康记录数据库中15501例银屑病患者的人群回顾性分析,评估不同生物治疗策略与炎症性关节炎发病时间的关联,发现累计发病率为每100人年2.6例银屑病关节炎。与TNF抑制剂治疗患者相比,处方IL-12/23或IL-23抑制剂的患者发生炎症性关节炎的风险显著更低,而IL-17抑制剂与TNF抑制剂之间风险无显著差异。作者指出缺乏前瞻性临床试验且回顾性分析结果相互矛盾,呼吁明确高风险生物标志物并开展前瞻性临床试验。
要点
- 在15501例银屑病患者中,炎症性关节炎累计发病率为每100人年2.6例。
- 与TNF抑制剂治疗患者相比,IL-12/23或IL-23抑制剂处方者发生炎症性关节炎的风险显著更低。
- IL-17抑制剂与TNF抑制剂之间发生炎症性关节炎的风险无显著差异。
核心结论
- 近期关于银屑病患者预防银屑病关节炎的数据支持明确高风险生物标志物并开展前瞻性临床试验的迫切需求,以就银屑病疾病拦截的可能性给出清晰指导。
研究设计与样本
- 基于美国电子健康记录数据库的人群回顾性分析,纳入15501例银屑病患者,评估不同生物治疗策略与炎症性关节炎发病时间的关联。
主要发现
- 累计发病率为每100人年2.6例银屑病关节炎。
- 多变量回归分析显示,与TNF抑制剂治疗患者相比,处方IL-12/23或IL-23抑制剂的患者发生炎症性关节炎的风险显著更低。
- 处方IL-17抑制剂的患者与TNF抑制剂治疗患者相比,发生炎症性关节炎的风险无显著差异。
局限性
- 由于研究设计,解释上存在一些局限性。
- 缺乏前瞻性临床试验,且来自临床试验或人群研究的回顾性数据分析显示相互矛盾的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal disease. Some studies suggest that targeted treatment may intercept the disease course and prevent psoriasis patients from developing PsA. A recent population-based retrospective analysis in 15 501 psoriasis patients evaluated the association between different biological treatment strategies and time to incident inflammatory arthritis based on data in a US electronic health records database. A cumulative incidence of 2.6 PsA cases per 100 person-years was determined. The multivariable regression analysis revealed a significantly lower risk of developing inflammatory arthritis in patients who had been prescribed interleukin (IL)-12/23 or IL-23 inhibitors compared with tumour necrosis factor (TNF) inhibitor-treated patients, whereas there was no significant difference in risk for patients prescribed inhibitors of IL-17 versus TNF. Although the analysis was based on a large set of clinical data and the findings were rigorously evaluated, there are some limitations in interpretation due to the study design. Prospective clinical trials are missing, and retrospective data analyses from clinical trials or population-based studies show conflicting results. Overall, the recent data on prevention of PsA in patients with psoriasis support the high need to characterise biomarkers of increased risk and perform prospective clinical trials to give a clear guidance on possibilities for disease interception in psoriatic disease.
引用
- Koehm M, Behrens F. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities. RMD Open. 2023. PMID: 37734874. doi:10.1136/rmdopen-2023-003166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。